MA44594B1 - Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci - Google Patents
Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ciInfo
- Publication number
- MA44594B1 MA44594B1 MA44594A MA44594A MA44594B1 MA 44594 B1 MA44594 B1 MA 44594B1 MA 44594 A MA44594 A MA 44594A MA 44594 A MA44594 A MA 44594A MA 44594 B1 MA44594 B1 MA 44594B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- ctla
- methods
- relates
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
La présente invention concerne des anticorps qui se lient spécifiquement à l'antigène ctla-4 humain et ont un effet antagoniste sur la fonction ctla-4. L'invention concerne également des compositions pharmaceutiques comprenant ces anticorps, des acides nucléiques codant pour ces anticorps, des vecteurs d'expression et des cellules hôtes permettant de fabriquer ces anticorps, et des méthodes de traitement d'un sujet à l'aide de ces anticorps.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562168391P | 2015-05-29 | 2015-05-29 | |
US201562182363P | 2015-06-19 | 2015-06-19 | |
US201562190653P | 2015-07-09 | 2015-07-09 | |
US201562257202P | 2015-11-18 | 2015-11-18 | |
US201662280263P | 2016-01-19 | 2016-01-19 | |
US201662292500P | 2016-02-08 | 2016-02-08 | |
US201662294558P | 2016-02-12 | 2016-02-12 | |
US201662323226P | 2016-04-15 | 2016-04-15 | |
PCT/US2016/034508 WO2016196237A1 (fr) | 2015-05-29 | 2016-05-27 | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
MA44594B1 true MA44594B1 (fr) | 2020-09-30 |
Family
ID=56118035
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA44594A MA44594B1 (fr) | 2015-05-29 | 2016-05-27 | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
MA053355A MA53355A (fr) | 2015-05-29 | 2016-05-27 | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053355A MA53355A (fr) | 2015-05-29 | 2016-05-27 | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
Country Status (26)
Country | Link |
---|---|
US (4) | US10144779B2 (fr) |
EP (2) | EP3303394B1 (fr) |
JP (2) | JP6900323B2 (fr) |
KR (2) | KR102492532B1 (fr) |
CN (2) | CN113603784A (fr) |
AU (3) | AU2016271591A1 (fr) |
BR (1) | BR112017025564B8 (fr) |
CA (1) | CA2986765A1 (fr) |
CL (1) | CL2017003023A1 (fr) |
CO (1) | CO2017013398A2 (fr) |
DK (1) | DK3303394T3 (fr) |
ES (1) | ES2803655T3 (fr) |
HK (1) | HK1253250A1 (fr) |
HR (1) | HRP20201031T1 (fr) |
HU (1) | HUE050750T2 (fr) |
IL (2) | IL255468B (fr) |
LT (1) | LT3303394T (fr) |
MA (2) | MA44594B1 (fr) |
MX (2) | MX2017015046A (fr) |
PE (1) | PE20180672A1 (fr) |
PL (1) | PL3303394T3 (fr) |
PT (1) | PT3303394T (fr) |
RS (1) | RS60792B1 (fr) |
SG (1) | SG10201913500TA (fr) |
SI (1) | SI3303394T1 (fr) |
WO (1) | WO2016196237A1 (fr) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3303394T3 (pl) | 2015-05-29 | 2020-11-16 | Agenus Inc. | Przeciwciała anty-ctla-4 i sposoby ich zastosowania |
BR112018003186A2 (pt) | 2015-09-01 | 2018-09-25 | Agenus Inc. | anticorpos anti-pd-1 e seus métodos de uso |
JO3739B1 (ar) | 2015-11-18 | 2021-01-31 | Merck Sharp & Dohme | روابط ctla4 |
PE20181535A1 (es) | 2015-12-16 | 2018-09-26 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
WO2017220989A1 (fr) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 et cytokines il-2 |
CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
CN107815468B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
EP3532504A1 (fr) | 2016-10-28 | 2019-09-04 | Bristol-Myers Squibb Company | Méthodes de traitement du carcinome urothélial au moyen d'un anticorps anti-pd -1 |
CA3046082A1 (fr) * | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anticorps et procedes d'utilisation de ceux-ci |
JP6992068B2 (ja) | 2016-12-07 | 2022-02-03 | アジェナス インコーポレイテッド | 抗ctla-4抗体およびそれらの使用方法 |
KR20240023449A (ko) | 2017-02-08 | 2024-02-21 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
EP4273258A3 (fr) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Protéines se liant à her2, nkg2d et cd16 |
US11319372B2 (en) * | 2017-02-21 | 2022-05-03 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4) |
MX2019009660A (es) * | 2017-02-28 | 2019-10-02 | Bristol Myers Squibb Co | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. |
SG10202110594UA (en) | 2017-03-31 | 2021-11-29 | Bristol Myers Squibb Co | Methods of treating tumor |
TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
CA3060618A1 (fr) | 2017-05-19 | 2018-11-22 | Wuxi Biologics (Shanghai) Co. Ltd. | Nouveaux anticorps monoclonaux diriges contre la proteine 4 associee aux lymphocytes t cytotoxiques (ctla-4) |
CN116478289A (zh) * | 2017-05-19 | 2023-07-25 | 上海药明生物技术有限公司 | 一种新的ctla-4单克隆抗体 |
WO2018222711A2 (fr) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprenant une combinaison d'un anticorps anti-lag-3, d'un inhibiteur de voie pd-1 et d'un agent immunothérapeutique |
KR20200028434A (ko) | 2017-07-14 | 2020-03-16 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
EP3675843A4 (fr) | 2017-08-31 | 2021-11-03 | IO Therapeutics, Inc. | Agonistes sélectifs de rar en association avec des modulateurs immunitaires en immunothérapie anticancéreuse |
AU2017432728A1 (en) * | 2017-09-21 | 2020-02-27 | Eucure (Beijing) Biopharma Co. Ltd. | Anti-CTLA4 antibodies and uses thereof |
EP3694532A4 (fr) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | Identification de néo-antigènes au moyen de points chauds |
US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
JP7201400B2 (ja) | 2017-11-14 | 2023-01-10 | ファイザー・インク | Ezh2阻害剤組合せ療法 |
JP2021503897A (ja) | 2017-11-22 | 2021-02-15 | グリットストーン オンコロジー インコーポレイテッド | 新生抗原のためのジャンクションエピトープ提示の低減 |
SG11202006823XA (en) | 2018-01-22 | 2020-08-28 | Bristol Myers Squibb Co | Compositions and methods of treating cancer |
JP2021512630A (ja) | 2018-02-08 | 2021-05-20 | ドラゴンフライ セラピューティクス, インコーポレイテッド | Nkg2d受容体を標的とする抗体可変ドメイン |
CN110272490B (zh) * | 2018-03-14 | 2021-05-14 | 上海开拓者生物医药有限公司 | 靶向ctla-4抗体、其制备方法和用途 |
WO2019179388A1 (fr) * | 2018-03-19 | 2019-09-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Nouveau polypeptide anticorps anti-ctla-4 |
US20210020264A1 (en) * | 2018-03-20 | 2021-01-21 | Cytomx Therapeutics, Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
WO2019183551A1 (fr) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Anticorps contre mica et/ou micb et leurs utilisations |
EP3774911A1 (fr) | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Méthodes de traitement de tumeur |
KR20210005106A (ko) | 2018-04-25 | 2021-01-13 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
EA202091888A1 (ru) * | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
US20210308123A1 (en) | 2018-08-16 | 2021-10-07 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
WO2020037092A1 (fr) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Modulateurs de nlrp3 dérivés d'imidazo [4,5-c]quinoléine |
BR112021002642A2 (pt) | 2018-08-16 | 2021-05-04 | Innate Tumor Immunity, Inc. | compostos de 4-amino-1h-imidazo[4,5-c]quinolina substituídos e métodos aprimorados para a preparação dos mesmos |
WO2020058762A1 (fr) * | 2018-09-20 | 2020-03-26 | Tikcro Technologies Ltd | Anticorps spécifiques dirigés contre ctla-4 et leurs utilisations |
EP3870609A1 (fr) | 2018-10-23 | 2021-09-01 | Bristol-Myers Squibb Company | Méthodes de traitement de tumeur |
NZ775959A (en) * | 2018-10-31 | 2022-08-26 | Bioatla Inc | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
KR20210093950A (ko) | 2018-11-16 | 2021-07-28 | 네오이뮨텍, 인코퍼레이티드 | Il-7 단백질 및 면역 관문 저해제의 조합으로 종양을 치료하는 방법 |
TW202033555A (zh) | 2018-11-16 | 2020-09-16 | 美商必治妥美雅史谷比公司 | 抗nkg2a抗體及其用途 |
KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
JP2022516881A (ja) * | 2018-12-26 | 2022-03-03 | キシリオ ディベロップメント インコーポレイテッド | 抗ctla4抗体およびその使用方法 |
JP2022516071A (ja) * | 2018-12-27 | 2022-02-24 | ギガジェン,インコーポレイティッド | 抗ctla-4結合タンパク質およびその使用方法 |
MX2021007860A (es) | 2018-12-28 | 2021-10-26 | Transgene | Poxvirux deficiente en m2. |
CN113301962A (zh) | 2019-01-14 | 2021-08-24 | 先天肿瘤免疫公司 | 用于治疗癌症的杂环nlrp3调节剂 |
KR20210114983A (ko) | 2019-01-14 | 2021-09-24 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
EP3911641A1 (fr) | 2019-01-14 | 2021-11-24 | Innate Tumor Immunity, Inc. | Modulateurs de nlrp3 |
KR20210114456A (ko) | 2019-01-14 | 2021-09-23 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 암의 치료에 사용하기 위한 nlrp3-조정제로서의 치환된 퀴나졸린 |
WO2020165374A1 (fr) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Molécule bifonctionnelle comprenant il-15ra |
CN113677402A (zh) | 2019-03-28 | 2021-11-19 | 百时美施贵宝公司 | ***的方法 |
WO2020198676A1 (fr) | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Méthodes de traitement de tumeur |
SG11202112021QA (en) | 2019-05-08 | 2021-11-29 | Janssen Biotech Inc | Materials and methods for modulating t cell mediated immunity |
WO2020243568A1 (fr) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet approprié pour une thérapie d'immuno-oncologie (i-o) |
JP2022534981A (ja) | 2019-05-30 | 2022-08-04 | ブリストル-マイヤーズ スクイブ カンパニー | 細胞局在化シグネチャーおよび組み合わせ治療 |
CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
WO2021041954A2 (fr) * | 2019-08-28 | 2021-03-04 | The Research Foundation For The State University Of New York | Administration ciblée d'enzymes modifiant la matrice tumorale |
AU2020350795A1 (en) | 2019-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Quantitative spatial profiling for LAG-3 antagonist therapy |
WO2021092221A1 (fr) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle |
WO2021092220A1 (fr) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle |
MX2022005474A (es) | 2019-11-08 | 2022-06-02 | Bristol Myers Squibb Co | Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3). |
TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | 包含il-7變體之雙官能分子 |
WO2021127554A1 (fr) | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinaisons d'inhibiteurs de dgk et d'antagonistes de points de contrôle |
AU2019479791A1 (en) | 2019-12-27 | 2022-07-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-CTLA-4 antibody and use thereof |
US20230348458A1 (en) | 2020-01-10 | 2023-11-02 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
JP2023514152A (ja) | 2020-02-06 | 2023-04-05 | ブリストル-マイヤーズ スクイブ カンパニー | Il-10およびその使用 |
WO2021216920A1 (fr) | 2020-04-22 | 2021-10-28 | Iovance Biotherapeutics, Inc. | Systèmes et procédés pour coordonner la fabrication de cellules pour l'immunothérapie spécifique au patient |
KR20230058442A (ko) | 2020-08-28 | 2023-05-03 | 브리스톨-마이어스 스큅 컴퍼니 | 간세포성 암종에 대한 lag-3 길항제 요법 |
WO2022047412A1 (fr) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Signature de localisation cellulaire et immunothérapie |
JP2023548051A (ja) | 2020-10-23 | 2023-11-15 | ブリストル-マイヤーズ スクイブ カンパニー | 肺がんのためのlag-3アンタゴニスト療法 |
UY39488A (es) * | 2020-10-28 | 2022-04-29 | Janssen Biotech Inc | Composiciones y métodos para modular la inmunidad mediada por la cadena delta gamma |
WO2022112198A1 (fr) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Procédé de sélection des thérapies optimales par points de contrôle immunitaire |
WO2022120179A1 (fr) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Signatures géniques multi-tumorales et leurs utilisations |
US20220233689A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Methods of treating tumors |
AU2021411486A1 (en) | 2020-12-28 | 2023-06-29 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2022212876A1 (fr) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Anticorps dirigés contre un cdcp1 clivé et leurs utilisations |
EP4320156A1 (fr) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp |
WO2022214653A1 (fr) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Nouvel échafaudage pour molécules bifonctionnelles présentant des propriétés améliorées |
AR126236A1 (es) | 2021-06-25 | 2023-10-04 | Chugai Pharmaceutical Co Ltd | Uso del anticuerpo anti-ctla-4 |
CN117616123A (zh) | 2021-06-25 | 2024-02-27 | 中外制药株式会社 | 抗ctla-4抗体 |
WO2023077034A1 (fr) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Méthodes de culture de cellules immunitaires |
CA3224890A1 (fr) | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Therapie par antagoniste de lag-3 pour cancer hematologique |
WO2023130081A1 (fr) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Procédé de traitement d'une tumeur avec une combinaison d'une protéine il-7 et d'un antagoniste du vegf |
CN114437220B (zh) * | 2022-01-24 | 2023-04-14 | 广东医科大学 | 一种抗ctla-4的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌及其应用 |
WO2023147371A1 (fr) | 2022-01-26 | 2023-08-03 | Bristol-Myers Squibb Company | Polythérapie pour carcinome hépatocellulaire |
WO2023164638A1 (fr) | 2022-02-25 | 2023-08-31 | Bristol-Myers Squibb Company | Polythérapie pour carcinome colorectal |
WO2023168404A1 (fr) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Méthodes de traitement d'une tumeur |
WO2023170606A1 (fr) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t |
WO2023178329A1 (fr) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Procédés d'isolement de polypeptides |
WO2023196987A1 (fr) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Méthodes de traitement d'une tumeur |
WO2023213763A1 (fr) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus codant pour un agent de liaison comprenant un sdab anti-pd-l1 |
WO2023213764A1 (fr) | 2022-05-02 | 2023-11-09 | Transgene | Polypeptide de fusion comprenant un anti-pd-l1 sdab et un membre du tnfsf |
WO2023235847A1 (fr) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Compositions d'anticorps et leurs procédés d'utilisation |
WO2024003353A1 (fr) | 2022-07-01 | 2024-01-04 | Transgene | Protéine de fusion comprenant une protéine d tensioactive et un élément de la tnfsf |
CN115845039A (zh) * | 2022-07-01 | 2023-03-28 | 可蓝赛生物医药(上海)有限公司 | 一种广谱多肽肿瘤疫苗组成 |
WO2024003360A1 (fr) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarqueurs et leurs utilisations pour le traitement du neuroblastome |
WO2024028386A1 (fr) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Molécule multifonctionnelle dirigée contre cd28 |
Family Cites Families (275)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
EP0216846B2 (fr) | 1985-04-01 | 1995-04-26 | Celltech Limited | Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotique employant cette lignee |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
IL91501A (en) | 1988-09-02 | 1998-03-10 | Dyax Corp | Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
WO1992009690A2 (fr) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees |
DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
EP0519596B1 (fr) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | Procédé pour réduire l'immunogénicité des domaines variables d'anticorps |
JPH07503124A (ja) | 1991-06-14 | 1995-04-06 | ゾーマ・コーポレーション | 微生物によって生産される抗体断片とそれらの複合体 |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
CA2103887C (fr) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US6024975A (en) | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP0672142B1 (fr) | 1992-12-04 | 2001-02-28 | Medical Research Council | Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
WO1995015982A2 (fr) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Procede de generation d'anticorps specifiques |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
ATE300610T1 (de) | 1994-01-31 | 2005-08-15 | Univ Boston | Bibliotheken aus polyklonalen antikörpern |
US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US5983134A (en) | 1995-04-23 | 1999-11-09 | Electromagnetic Bracing Systems Inc. | Electrophoretic cuff apparatus drug delivery system |
EP0822830B1 (fr) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Anticorps anti-IL-8 dérivés de xenosouris immunisées |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US6167301A (en) | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
AU6873396A (en) | 1995-10-16 | 1997-05-07 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6027947A (en) | 1996-08-20 | 2000-02-22 | Ramtron International Corporation | Partially or completely encapsulated top electrode of a ferroelectric capacitor |
US5985317A (en) | 1996-09-06 | 1999-11-16 | Theratech, Inc. | Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents |
WO1998014179A1 (fr) | 1996-10-01 | 1998-04-09 | Cima Labs Inc. | Compositions en microcapsule a masquage de gout et procedes de fabrication |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
CA2722378C (fr) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Anticorps humains qui se lient au tnf.alpha. |
US20060034844A1 (en) | 1996-12-04 | 2006-02-16 | The Regents Of The University Of California | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
US5860957A (en) | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
WO1998042752A1 (fr) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Peptides immunotherapeutiques se liant a ctla-4 |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
EP0968711B9 (fr) | 1997-10-28 | 2008-05-28 | Bando Chemical Industries, Ltd. | Feuille de timbre cutane et procede de production d'une feuille de base pour timbre |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
CA2323746A1 (fr) | 1998-03-19 | 1999-09-23 | Heska Corporation | Nouvelles formes de proteines de co-stimulation des lymphocytes t, molecules d'acide nucleique et leur utilisation |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
AU774962B2 (en) | 1998-12-03 | 2004-07-15 | Regents Of The University Of California, The | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
WO2001014557A1 (fr) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, recepteur de b7-4, et son utilisation |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
ES2629683T3 (es) | 1999-11-30 | 2017-08-14 | Mayo Foundation For Medical Education And Research | B7-H1, una nueva molécula inmunorreguladora |
EP1261376A1 (fr) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Anticorps contre ctla4 (cd152), conjugues comprenant lesdits anticorps, et leurs utilisations |
US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
WO2001079300A1 (fr) | 2000-04-12 | 2001-10-25 | Genetics Institute, Llc. | Antigene a liaison de surface reliant des portions d'anticorps se liant au ctla-4 et au cd28 et applications |
ES2295228T3 (es) * | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
WO2004006955A1 (fr) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Anticorps super humanises |
WO2003042402A2 (fr) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents modulant l'activite de cellules immunes et procedes d'utilisation associes |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
NZ536420A (en) | 2002-04-12 | 2008-04-30 | Medarex Inc | Methods of treatment using CTLA-4 antibodies |
JP2005533015A (ja) | 2002-05-02 | 2005-11-04 | ユニバーシティー オブ コネティカット ヘルス センター | 抗体療法の有効性を増強するための熱ショックタンパク質の使用 |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
DE10161767T1 (de) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
EP1549678A4 (fr) | 2002-09-30 | 2006-01-18 | Pfizer Prod Inc | Hybridomes generant des taux eleves d'anticorps contre des sequences humaines |
US7521051B2 (en) | 2002-12-23 | 2009-04-21 | Medimmune Limited | Methods of upmodulating adaptive immune response using anti-PD-1 antibodies |
US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
WO2005035575A2 (fr) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanisation d'anticorps |
EP1732600A2 (fr) | 2004-03-26 | 2006-12-20 | Pfizer Products Incorporated | Utilisations d'anticorps anti-ctla-4 |
US7494779B2 (en) | 2004-06-14 | 2009-02-24 | Li-Te Chin | Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist |
US20060057626A1 (en) | 2004-09-03 | 2006-03-16 | Nichol Geoffrey M | Assessment of CTLA-4 polymorphisms in CTLA-4 blockade therapy |
US20090252741A1 (en) | 2004-09-08 | 2009-10-08 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
DE102004063494A1 (de) | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
WO2006096488A2 (fr) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Compositions d'anticorps en plateau |
US20060240006A1 (en) * | 2005-04-20 | 2006-10-26 | Chishih Chu | Novel antibody structures derived from human germline sequences |
AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
JP2006327937A (ja) | 2005-05-23 | 2006-12-07 | Ritsutoku Kin | ヒト胚細胞系遺伝子構造を具えたヒト抗体構造及びその誘導フラグメント |
SI1907000T2 (sl) | 2005-06-08 | 2020-07-31 | Dana-Farber Cancer Institute | Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
WO2007056539A2 (fr) | 2005-11-08 | 2007-05-18 | Medarex, Inc. | Prevention et traitement de l'enterocolite associee a un traitement par anticorps anti-ctla-4 |
CA2630157C (fr) | 2005-12-07 | 2018-01-09 | Medarex, Inc. | Regimes d'escalade de dose d'anticorps ctla-4 |
CN101822820A (zh) | 2005-12-20 | 2010-09-08 | 布里斯托尔—迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ctla−4抗体の限局性分泌のための方法および組成物 |
US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
EP2007423A2 (fr) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Polythérapie à base d'un anticorps anti-ctla4 |
CN101074264B (zh) | 2006-05-17 | 2011-08-17 | 上海抗体药物国家工程研究中心有限公司 | 一种重组抗ctla4单克隆抗体及其制备方法和用途 |
WO2008071447A2 (fr) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Séquences d'acides aminés qui modulent l'interaction entre des cellules du système immunitaire |
WO2008100562A2 (fr) * | 2007-02-14 | 2008-08-21 | Medical College Of Georgia Research Institute, Inc. | Indole-amine 2,3-dioxygénase, voies pd-1/pd-l et voies ctla4 dans l'activation des lymphocytes t régulateurs |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
EP3124046B1 (fr) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Thérapies combinées utilisant des molécules de liaison gitr |
PE20120259A1 (es) | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
US7968300B2 (en) | 2007-11-21 | 2011-06-28 | Li-Te Chin | Method of isolating regulatory T cells from human samples |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
EP2227296B1 (fr) | 2008-01-08 | 2015-11-25 | Bristol-Myers Squibb Company | Combinaison d'anticorps anti-ctla4 avec des agents de modulation de la tubuline pour le traitement de maladies prolifératives |
WO2009100140A1 (fr) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anticorps anti-clta-4 avec blocage réduit de la liaison de ctla-4 à b7 et leurs utilisations |
US8747847B2 (en) | 2008-02-11 | 2014-06-10 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
EP2262837A4 (fr) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
DK2824100T3 (en) | 2008-07-08 | 2018-04-16 | Incyte Holdings Corp | 1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase |
US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
PE20110435A1 (es) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
KR102097887B1 (ko) | 2008-09-26 | 2020-04-06 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도 |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
JP5589077B2 (ja) * | 2009-07-20 | 2014-09-10 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患の相乗的処置のための抗ctla4抗体と多様な治療レジメンとの組み合わせ |
JP5883384B2 (ja) | 2009-08-13 | 2016-03-15 | ザ ジョンズ ホプキンス ユニバーシティー | 免疫機能を調節する方法 |
AU2010308030B2 (en) | 2009-10-12 | 2014-05-29 | Pfizer Inc. | Cancer treatment |
GB0920258D0 (en) | 2009-11-19 | 2010-01-06 | Alligator Bioscience Ab | New medical agents and use thereof |
HUE037159T2 (hu) | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
CN102134276A (zh) | 2010-01-22 | 2011-07-27 | 上海抗体药物国家工程研究中心有限公司 | 一种抗ctla-4嵌合抗体 |
WO2011100841A1 (fr) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Modulation de pd-1 et utilisations de celle-ci pour moduler la réplication du vih |
WO2011110604A1 (fr) | 2010-03-11 | 2011-09-15 | Ucb Pharma, S.A. | Anticorps pd-1 |
CA2794708C (fr) | 2010-03-29 | 2021-11-16 | Zymeworks Inc. | Anticorps presentant une fonction effectrice amelioree ou supprimee |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
JP2014517846A (ja) * | 2011-05-25 | 2014-07-24 | メルク・シャープ・アンド・ドーム・コーポレーション | 改善された特性を有するFc含有ポリペプチドの製造方法 |
EP2723381A4 (fr) | 2011-06-21 | 2015-03-18 | Univ Johns Hopkins | Rayonnement focalisé pour améliorer les thérapies basées sur l'immunité contre les néoplasmes |
LT2734551T (lt) | 2011-07-24 | 2018-04-10 | Cure Tech Ltd. | Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai |
EP3939613A1 (fr) | 2011-08-11 | 2022-01-19 | ONO Pharmaceutical Co., Ltd. | Agent thérapeutique destiné à des maladies auto-immunes comprenant un agoniste de pd-1 |
US8920075B2 (en) | 2011-09-01 | 2014-12-30 | Halo Maritime Defense Systems, Inc. | Marine barrier and gate |
US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
CA2865153C (fr) | 2012-02-23 | 2022-11-22 | Sloan-Kettering Institute For Cancer Research | Prediction de la sensibilite a un traitement par des produits therapeutiques d'immunomodulation et procede de surveillance des effets ascopaux au cours d'un tel traitement |
US20150079100A1 (en) | 2012-03-23 | 2015-03-19 | Bristol-Myers Squibb Company | Methods of treatments using ctla-4 antibodies |
MX359257B (es) | 2012-05-04 | 2018-09-19 | Pfizer | Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna. |
WO2013169388A1 (fr) | 2012-05-08 | 2013-11-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Biomarqueurs prédictifs dans le cadre d'une thérapie basée sur le blocage du ctla-4 et d'une thérapie basée sur le blocage de la pd-1 |
SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
CN115093480A (zh) | 2012-05-31 | 2022-09-23 | 索伦托药业有限公司 | 与pd-l1结合的抗原结合蛋白 |
WO2013192546A1 (fr) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Anticorps activables ayant des fragments stériques ne se liant pas et leurs procédés d'utilisation |
KR20150037857A (ko) | 2012-06-22 | 2015-04-08 | 싸이톰스 테라퓨틱스, 인크. | 항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법 |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳-法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
WO2014066532A1 (fr) | 2012-10-23 | 2014-05-01 | Bristol-Myers Squibb Company | Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer |
EP2911669B1 (fr) | 2012-10-26 | 2024-04-10 | The University of Chicago | Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
JP6605957B2 (ja) | 2013-01-04 | 2019-11-13 | シトムクス セラピューティクス,インコーポレイティド | 生体系におけるプロテアーゼ活性を検出するための組成物及び方法 |
ME03796B (fr) | 2013-03-15 | 2021-04-20 | Glaxosmithkline Ip Dev Ltd | Protéines de liaison anti-lag-3 |
ES2699599T3 (es) | 2013-03-15 | 2019-02-11 | Abbvie Biotherapeutics Inc | Variantes de Fc |
EP2992086B1 (fr) | 2013-04-30 | 2020-09-30 | La Jolla Institute for Allergy and Immunology | Modulation de la fonction régulatrice des cellules t par l'intermédiaire d'une protéine kinase c-eta |
US9815897B2 (en) | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
CN105683217B (zh) | 2013-05-31 | 2019-12-10 | 索伦托治疗有限公司 | 与pd-1结合的抗原结合蛋白 |
WO2014209804A1 (fr) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Anticorps bispécifiques |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
BR112016000853A2 (pt) | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
WO2015016718A1 (fr) | 2013-08-02 | 2015-02-05 | Bionovion Holding B.V. | Combinaison d'agonistes cd27 et d'inhibiteurs de points de contrôle immunitaires pour une stimulation immune |
WO2015024042A1 (fr) | 2013-08-22 | 2015-02-26 | The Council Of The Queensland Institute Of Medical Research | Modulation d'immunorécepteur permettant le traitement de cancer et d'infections virales |
WO2015035112A1 (fr) | 2013-09-05 | 2015-03-12 | The Johns Hopkins University | Thérapie anticancéreuse par l'intermédiaire d'une combinaison de modulation épigénétique et modulation immunitaire |
US10077305B2 (en) | 2013-09-10 | 2018-09-18 | Medimmune Limited | Antibodies against PD-1 and uses thereof |
CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
SG11201601763SA (en) | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
EP3757130A1 (fr) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Méthodes de traitement de cancers hématologiques |
US9968674B2 (en) | 2013-10-18 | 2018-05-15 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody |
US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
CN104558177B (zh) | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
WO2015069770A1 (fr) | 2013-11-05 | 2015-05-14 | Cognate Bioservices, Inc. | Combinaisons d'inhibiteurs de point de contrôle et d'agents thérapeutiques pour traiter un cancer |
DK3081576T3 (da) | 2013-12-12 | 2019-10-21 | Shanghai hengrui pharmaceutical co ltd | Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf |
DK3094351T3 (da) | 2014-01-15 | 2022-02-21 | Kadmon Corp Llc | Immunmodulatoriske midler |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
PL3556775T3 (pl) | 2014-01-28 | 2022-01-31 | Bristol-Myers Squibb Company | Przeciwciała anty-lag-3 w leczeniu nowotworów hematologicznych |
US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
WO2015134605A1 (fr) | 2014-03-05 | 2015-09-11 | Bristol-Myers Squibb Company | Traitement du cancer du rein à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux |
KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
WO2015153820A1 (fr) | 2014-04-02 | 2015-10-08 | Felder Mitchell S | Blocage de ctl-4 combiné à la chimiothérapie métronomique pour le traitement du cancer |
WO2015176033A1 (fr) | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Traitement du cancer du poumon à l'aide d'une combinaison d'un anticorps anti-pd-1 et d'un autre agent anticancéreux |
EP3149042B1 (fr) | 2014-05-29 | 2019-08-28 | Spring Bioscience Corporation | Anticorps dirigés contre pd-l1 et leurs utilisations |
WO2015195163A1 (fr) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Anticorps totalement humain anti-pd-l1 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
HUE045108T2 (hu) | 2014-07-16 | 2019-12-30 | Transgene Sa | Onkolitikus vírus immunellenõrzõpont-modulátorok expresszálására |
CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
ES2847311T3 (es) | 2014-08-05 | 2021-08-02 | MabQuest SA | Reactivos inmunológicos que se unen a PD-1 |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
WO2016030455A1 (fr) | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anticorps anti-b7-h1 et anti-ctla -4 pour le traitement du cancer du poumon non à petites cellules |
BR112016030670A2 (pt) | 2014-08-29 | 2017-10-31 | Hoffmann La Roche | "imunocitoquina" |
US11344620B2 (en) | 2014-09-13 | 2022-05-31 | Novartis Ag | Combination therapies |
WO2016054555A2 (fr) | 2014-10-03 | 2016-04-07 | Novartis Ag | Polythérapies |
AU2015333687B2 (en) | 2014-10-14 | 2021-03-18 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to PD-L1 and uses thereof |
US20190076452A1 (en) | 2014-11-11 | 2019-03-14 | Medimmune Limited | Therapeutic combinations for treating neoplasia |
KR20230030022A (ko) | 2014-11-13 | 2023-03-03 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
BR112017010101A2 (pt) | 2014-12-16 | 2018-01-02 | Bristol Myers Squibb Co | uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central |
EP3233918A1 (fr) | 2014-12-19 | 2017-10-25 | Novartis AG | Polythérapies |
JP6797803B2 (ja) | 2014-12-31 | 2020-12-09 | セルジーン コーポレイション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
WO2016130986A1 (fr) | 2015-02-13 | 2016-08-18 | Sorrento Therapeutics, Inc. | Anticorps thérapeutiques se liant à ctla4 |
WO2016149387A1 (fr) | 2015-03-18 | 2016-09-22 | The Johns Hopkins University | Privation androgénique avec blocage de point de contrôle immunitaire retardant le développement du cancer de la prostate résistant à la castration |
US20180094058A1 (en) | 2015-04-17 | 2018-04-05 | Bioxcel Corporation | Compositions and methods for preventing tumor growth and treating cancer by targeting lectin galactoside-binding soluble 3 binding protein |
US20180134771A1 (en) | 2015-05-07 | 2018-05-17 | Bioxcel Corporation | Novel immunomodulatory therapeutic strategies targeting tumors in cancer |
WO2016183469A1 (fr) | 2015-05-13 | 2016-11-17 | Robert Kirken | Blocage anti-ctla -4 |
US20160347848A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
PL3303394T3 (pl) | 2015-05-29 | 2020-11-16 | Agenus Inc. | Przeciwciała anty-ctla-4 i sposoby ich zastosowania |
WO2016196389A1 (fr) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Traitement du néphrocarcinome |
WO2016197067A1 (fr) | 2015-06-05 | 2016-12-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Vaccin gm-csf/cd40l et polythérapie d'inhibiteur de point de contrôle |
JP2018522887A (ja) | 2015-07-14 | 2018-08-16 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 免疫チェックポイント阻害剤を使用する癌の処置法 |
EP3331917A1 (fr) | 2015-08-04 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Traitements de combinaison et utilisations et procédés associés |
US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
WO2017062615A2 (fr) | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Polythérapie pour le traitement du cancer |
WO2017079303A1 (fr) | 2015-11-02 | 2017-05-11 | The Cleveland Clinic Foundation | Thérapie ciblant les points de contrôle immunitaires orchestrée séquentiellement pour le traitement et la prévention du cancer |
BR112018012113A2 (pt) | 2015-12-15 | 2018-12-04 | Oncoimmune Inc | anticorpos monoclonais de ctla4 anti-humana quiméricos e humanizados e usos dos mesmo |
TWI808934B (zh) | 2015-12-31 | 2023-07-21 | 美商伯克利之光生命科技公司 | 經工程化以表現促發炎多肽之腫瘤浸潤細胞 |
MA43587A (fr) | 2016-01-10 | 2018-11-14 | Modernatx Inc | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 |
EP3407911B1 (fr) | 2016-01-28 | 2022-05-18 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Procédés et composition pharmaceutique pour le traitement du cancer |
US20170233476A1 (en) | 2016-02-12 | 2017-08-17 | Sorrento Therapeutics, Inc. | Antibody Therapeutics That Bind CTLA4 |
EP3213768A1 (fr) | 2016-03-01 | 2017-09-06 | LODOCO CLINICAL Kft | Combination d'une dose base d'une blockade de checkpoint immnunologique avec une dose élevée de il-2 pour le traitement du cancer métastatique |
EP3423087B1 (fr) | 2016-03-04 | 2023-11-15 | IO Biotech APS | Thérapie combinée contre le cancer |
EP3426271A4 (fr) | 2016-03-10 | 2019-10-16 | Cold Genesys, Inc. | Méthodes de traitement de tumeurs solides ou lymphatiques par polythérapie |
WO2017160717A2 (fr) | 2016-03-15 | 2017-09-21 | Memorial Sloan Kettering Cancer Center | Méthode de traitement de maladies à l'aide de modulateurs de kinases |
SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
CN107400166A (zh) | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
WO2017201502A1 (fr) | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Utilisation d'agents de modulation du glutamate avec des immunothérapies pour traiter le cancer |
CA3046082A1 (fr) * | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anticorps et procedes d'utilisation de ceux-ci |
JP6992068B2 (ja) * | 2016-12-07 | 2022-02-03 | アジェナス インコーポレイテッド | 抗ctla-4抗体およびそれらの使用方法 |
-
2016
- 2016-05-27 PL PL16728509T patent/PL3303394T3/pl unknown
- 2016-05-27 KR KR1020177037545A patent/KR102492532B1/ko active IP Right Grant
- 2016-05-27 WO PCT/US2016/034508 patent/WO2016196237A1/fr active Application Filing
- 2016-05-27 CN CN202111057251.XA patent/CN113603784A/zh active Pending
- 2016-05-27 MX MX2017015046A patent/MX2017015046A/es unknown
- 2016-05-27 AU AU2016271591A patent/AU2016271591A1/en not_active Abandoned
- 2016-05-27 BR BR112017025564A patent/BR112017025564B8/pt active IP Right Grant
- 2016-05-27 HU HUE16728509A patent/HUE050750T2/hu unknown
- 2016-05-27 US US15/166,305 patent/US10144779B2/en active Active
- 2016-05-27 EP EP16728509.7A patent/EP3303394B1/fr active Active
- 2016-05-27 PT PT167285097T patent/PT3303394T/pt unknown
- 2016-05-27 RS RS20200805A patent/RS60792B1/sr unknown
- 2016-05-27 DK DK16728509.7T patent/DK3303394T3/da active
- 2016-05-27 EP EP20168222.6A patent/EP3736290A1/fr active Pending
- 2016-05-27 MA MA44594A patent/MA44594B1/fr unknown
- 2016-05-27 PE PE2017002485A patent/PE20180672A1/es unknown
- 2016-05-27 JP JP2017561965A patent/JP6900323B2/ja active Active
- 2016-05-27 ES ES16728509T patent/ES2803655T3/es active Active
- 2016-05-27 KR KR1020237002568A patent/KR20230028478A/ko not_active Application Discontinuation
- 2016-05-27 CA CA2986765A patent/CA2986765A1/fr active Pending
- 2016-05-27 SI SI201630827T patent/SI3303394T1/sl unknown
- 2016-05-27 CN CN201680042887.8A patent/CN107849144B/zh active Active
- 2016-05-27 LT LTEP16728509.7T patent/LT3303394T/lt unknown
- 2016-05-27 MA MA053355A patent/MA53355A/fr unknown
- 2016-05-27 SG SG10201913500TA patent/SG10201913500TA/en unknown
-
2017
- 2017-11-06 IL IL255468A patent/IL255468B/en unknown
- 2017-11-23 MX MX2023000818A patent/MX2023000818A/es unknown
- 2017-11-28 CL CL2017003023A patent/CL2017003023A1/es unknown
- 2017-12-26 CO CONC2017/0013398A patent/CO2017013398A2/es unknown
-
2018
- 2018-09-29 HK HK18112539.3A patent/HK1253250A1/zh unknown
- 2018-10-19 US US16/165,833 patent/US10479833B2/en active Active
-
2019
- 2019-06-28 AU AU2019204586A patent/AU2019204586C1/en active Active
-
2020
- 2020-04-24 US US16/858,195 patent/US11267889B2/en active Active
- 2020-06-30 HR HRP20201031TT patent/HRP20201031T1/hr unknown
-
2021
- 2021-06-16 JP JP2021100134A patent/JP7456976B2/ja active Active
- 2021-08-03 AU AU2021211991A patent/AU2021211991A1/en active Pending
-
2022
- 2022-01-24 US US17/582,839 patent/US20220267443A1/en active Pending
- 2022-03-27 IL IL291711A patent/IL291711A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA44594B1 (fr) | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci | |
MA50949B1 (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
CO2018013471A2 (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco | |
CY1122804T1 (el) | Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα) | |
MA42542B1 (fr) | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes | |
MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
MA44334A (fr) | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll | |
EA201891909A1 (ru) | TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ | |
EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
EA201691266A1 (ru) | Анти-cd3 антитела и способы применения | |
EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
MA47442A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active | |
MA40682A (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
EA201391342A1 (ru) | Cd37-связывающие молекулы и их иммуноконъюгаты | |
MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
EA202192405A1 (ru) | Составы антител против il-36r | |
MA39342B2 (fr) | Anticorps il -21 | |
EA201592285A1 (ru) | Антигенсвязывающие белки к рецептору онкостатина м | |
BR112022001575A2 (pt) | Formulações de anticorpos anti-pvrig e usos dos mesmos | |
MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif | |
EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM |